<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801914</url>
  </required_header>
  <id_info>
    <org_study_id>717/11</org_study_id>
    <nct_id>NCT04801914</nct_id>
  </id_info>
  <brief_title>Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia Before and After PTBD</brief_title>
  <official_title>Influence of Percutaneous Biliary Drainage on the Change of Enzyme Activity of Matrix Metalloproteinases in the Serum of Patients With Malignant Obstructive Hyperbilirubinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut za Rehabilitaciju Sokobanjska Beograd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kliniƒçki centar Srbije</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut za Rehabilitaciju Sokobanjska Beograd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to detect differences in the enzymatic activity of matrix&#xD;
      metalloproteinases in patients with malignant obstructive hyperbilirubinemia before and after&#xD;
      percutaneous biliary drainage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be designed as a prospective cohort study involving the collection of&#xD;
      peripheral blood samples before and one month after percutaneous biliary drainage for further&#xD;
      molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).&#xD;
      Biochemical analyzes are preceded by the entry of data relevant to the research (demographic,&#xD;
      anamnestic, clinical and biochemical).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">May 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMP-2 and MMP-9 serum activity</measure>
    <time_frame>during intervention</time_frame>
    <description>MMP serume activity will be measured by molecular biochemical analysis performed on peripheral blood samples taken before and one month after percutaneous biliary drainage</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Matrix Metalloproteinase</condition>
  <arm_group>
    <arm_group_label>Matrix Metalloproteinases</arm_group_label>
    <description>Value of serum matrix metalloproteinase activity before and one month after PTBD</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous biliary drainage</intervention_name>
    <description>Collection of peripheral blood samples before and one month after percutaneous biliary drainage performed for patients with malignant obstructive hyperbilirubinemia for further molecular biochemical analysis (measurement of serum matrix metalloproteinase activity).</description>
    <arm_group_label>Matrix Metalloproteinases</arm_group_label>
    <other_name>Matrix Metalloproteinase serum activity measurement</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with malignant obstructive hyperbilirubinemia admitted to hospital and referred to&#xD;
        the interventional radiologist for percutaneous biliary drainage.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        pathological confirmation or imaging data confirming malignant disease causing bile duct&#xD;
        obstruction, performance status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        terminally ill patients, performance status &gt;2, hepatic decompensation, severe underlying&#xD;
        cardiac or renal diseases and coagulation disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristina Gopcevic, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Institute for chemistry in medicine, Medical school, University of Belgrade</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksandar N Filipovic, Dr</last_name>
    <phone>+381658832505</phone>
    <email>aleksandar.filipovic11@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar N Filipovic, Dr</last_name>
      <phone>+381658832505</phone>
      <email>aleksandar.filipovic11@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 13, 2021</last_update_submitted>
  <last_update_submitted_qc>March 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut za Rehabilitaciju Sokobanjska Beograd</investigator_affiliation>
    <investigator_full_name>Tamara Filipovic</investigator_full_name>
    <investigator_title>Phd</investigator_title>
  </responsible_party>
  <keyword>biliary drainage, matrix metalloproteinases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia</mesh_term>
    <mesh_term>Jaundice, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

